文献速递贫血与红细胞疾病

西班牙裔镰状细胞贫血儿童卒中预防:SACRED试验

Stroke prevention in Hispanic children with sickle cell anemia: the SACRED trial.
PubMed 文献 · Blood Adv · 2025-01-01

SACRED试验在多米尼加共和国纳入283例西班牙裔镰状细胞贫血儿童,建立经颅多普勒(TCD)筛查并给予羟基脲治疗。固定剂量羟基脲6个月使57例初治患儿平均TCD流速下降20 cm/s,61%恢复正常;剂量递增至最大耐受剂量(MTD)后镰状相关事件发生率比为0.59(95%CI 0.36–0.98,P=0.0420),MTD治疗5年内TCD获益持续,81%恢复正常,平均流速下降27 cm/s。

要点

  • 初筛时条件流速(170–199 cm/s)初治患儿较正常流速(<170 cm/s)者更年轻且贫血更重。
  • 57例初治患儿固定剂量羟基脲20 mg/kg/日治疗6个月,平均TCD流速下降20 cm/s,61%恢复正常。
  • 剂量递增至MTD较固定剂量减少镰状相关事件,发生率比0.59(95%CI 0.36–0.98,P=0.0420)。

核心结论

  • SACRED试验记录西班牙裔镰状细胞贫血儿童脑血管病高负担,并证明合作建立TCD筛查项目可行、羟基脲可降低TCD流速和卒中风险、剂量递增获益持续。

研究设计与样本

  • SACRED试验为在多米尼加共和国开展的干预性试验,纳入283例镰状细胞贫血儿童,平均年龄8.7±3.4岁,女童130例(46%)。
  • 10名多米尼加医学毕业生经培训获得TCD检查资格并接受羟基脲管理培训。
  • 试验注册号NCT02769845。

主要发现

  • 初筛时条件流速(170–199 cm/s)初治患儿较正常流速(<170 cm/s)患儿更年轻(6.6±2.7 vs 8.9±3.4岁,P=0.0002)且血红蛋白更低(7.4±0.8 vs 8.0±1.2 g/dL,P=0.0046)。
  • 57例初治患儿接受固定剂量羟基脲20 mg/kg/日治疗6个月,平均TCD流速下降20 cm/s,61%恢复正常。
  • 剂量递增至MTD较固定剂量减少镰状相关事件,发生率比0.59(95%CI 0.36–0.98,P=0.0420)。
  • MTD治疗5年内TCD获益持续,81%恢复正常,平均TCD流速下降27 cm/s。
  • 脑磁共振成像显示基线实质病变显著;治疗期间10%出现新血管病变,另有1例卒中及1例死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sickle cell anemia (SCA) is recognized globally, but little is known about affected Hispanic populations. In partnership with the Dominican Republic, a Hispanic Caribbean island with a large SCA population, a transcranial Doppler (TCD) screening program provided hydroxyurea to children with conditional velocities. Building local capacity, 10 Dominican medical graduates were certified in TCD examinations and trained in hydroxyurea management. The Stroke Avoidance for Children in REpública Dominicana (SACRED) trial enrolled 283 children with average age of 8.7 ± 3.4 years and 130 (46%) females. At initial screening, treatment-naïve children with conditional velocities (170-199 cm/s) were younger (6.6 ± 2.7 vs 8.9 ± 3.4 years; P = .0002) and more anemic (hemoglobin, 7.4 ± 0.8 vs 8.0 ± 1.2 g/dL; P = .0046) than children with normal screening velocities (<170 cm/s). Among 57 treatment-naïve children receiving 6 months of fixed-dose hydroxyurea at 20 mg/kg per day, average TCD velocities decreased by 20 cm/s, and 61% became normal. Compared with fixed-dose hydroxyurea, dose escalation to maximum tolerated dose (MTD) led to fewer sickle-related events with incidence rate ratio 0.59, 95% confidence intervals 0.36 to 0.98, P = .0420. At MTD, TCD benefits were sustained over 5 years, with 81% reverting to normal and an average TCD velocity decrease of 27 cm/s. Brain magnetic resonance imaging documented substantial baseline parenchymal disease; during treatment, 10% developed new vasculopathy, plus 1 stroke and 1 death. The SACRED trial documents a high burden of cerebrovascular disease among Hispanic children with SCA and demonstrates the feasibility of partnership to establish TCD screening programs, the utility of hydroxyurea to reduce TCD velocities and reduce stroke risk, and sustained benefits of hydroxyurea dose escalation. This trial was registered at www.clinicaltrials.gov as #NCT02769845.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nieves RM, Latham T, Marte N, et al. Stroke prevention in Hispanic children with sickle cell anemia: the SACRED trial. Blood Adv. 2025. PMID: 39820633. doi:10.1182/bloodadvances.2024014327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。